Natco Pharma Ltd Share Price & Stock Analysis

Natco Pharma Ltd (NSE: NATCOPHARM, BSE: 524816) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹15,869 Cr, it ranks #436 by market cap among the 6,197 Indian listed companies on FinBizNet, and #18 of 86 in Medicinal Chemicals and Botanical Products. At ₹808.00 (as of 16 Nov 2026), the share price is 34.1% below its 52-week high of ₹1,226.80 and 4.4% above its 52-week low of ₹773.60. The share price is up 1.0% over one year and down 14.8% over three months.

Key Metrics

Current Price₹808.00
Market Cap₹15,869 Cr
NSE SymbolNATCOPHARM
BSE Code524816
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio10.2
Return on Equity16.85%
Return on Assets7.98%
52-Week Range₹773.60 – ₹1,226.80
1-Year Price Change+1.0%
3-Month Price Change-14.8%
Beta (1Y)0.17
Dividend Yield0.56%
HeadquartersHyderabad, Telangana
Websitewww.natcopharma.co.in

Latest Quarterly Results — Q2 FY27

Revenue₹967 Cr
Net Profit₹203 Cr
Net Margin20.9%
EPS (Basic)₹11.31
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Natco Pharma Ltd Quarterly Revenue and Profit Trend

Natco Pharma Ltd reported revenue of ₹967 Cr in Q2 FY27, down 29.0% from ₹1,363 Cr in Q2 FY26 and up 31.6% from ₹735 Cr in Q1 FY27. It posted a net profit of ₹203 Cr for the quarter, against a net profit of ₹518 Cr in Q2 FY26 (down 60.9%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹647 Cr (Q3 FY26) to ₹1,363 Cr (Q2 FY26). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹967 Cr₹203 Cr20.9%
Q1 FY27₹735 Cr₹207 Cr28.1%
Q4 FY26₹739 Cr₹269 Cr36.4%
Q3 FY26₹647 Cr₹151 Cr23.4%
Q2 FY26₹1,363 Cr₹518 Cr38.0%
Q1 FY26₹1,329 Cr₹480 Cr36.1%
Q4 FY25₹1,221 Cr₹406 Cr33.3%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 46.22% of Natco Pharma Ltd's shares as of Oct 2026, against 49.48% in Dec 2025 (−3.26 percentage points). Delivery averaged 52.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Natco Pharma Ltd

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of i

Products and Services

1. Pharmaceuticals-This segment develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients. 2. Agro Chemicals-This segment offers agro chemicals. 3. Unallocated-0 4. Segment Adjustment-0

Business Segments

1. Pharmaceuticals-96.6% 2. Agro Chemicals-3.4%

Natco Pharma Ltd vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Natco Pharma Ltd₹15,869 Cr10.216.85%₹967 Cr+1.0%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Natco Pharma Ltd?

Natco Pharma Ltd is trading at ₹808.00, with a market capitalisation of ₹15,869 Cr.

Which sector does Natco Pharma Ltd belong to?

Natco Pharma Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Natco Pharma Ltd?

Natco Pharma Ltd has a P/E of 10.2 and a return on equity of 16.85%.

What is the stock symbol of Natco Pharma Ltd?

Natco Pharma Ltd is listed on the NSE under the symbol NATCOPHARM and on the BSE under the scrip code 524816.

How has Natco Pharma Ltd's share price moved over the past year?

Natco Pharma Ltd's share price is up 1.0% over one year and down 14.8% over three months. Its 52-week range is ₹773.60 to ₹1,226.80.

What were Natco Pharma Ltd's latest quarterly results?

In Q2 FY27, Natco Pharma Ltd reported revenue of ₹967 Cr and net profit of ₹203 Cr, with basic EPS of ₹11.31 (consolidated, parsed from the company's exchange filing).

How have Natco Pharma Ltd's revenue and profit changed over the past year?

Natco Pharma Ltd reported revenue of ₹967 Cr in Q2 FY27, down 29.0% from ₹1,363 Cr in Q2 FY26 and up 31.6% from ₹735 Cr in Q1 FY27.

What is the promoter holding in Natco Pharma Ltd?

Promoters held 46.22% of Natco Pharma Ltd's shares as of Oct 2026, against 49.48% in Dec 2025 (−3.26 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.